)
Esperion Therapeutics (ESPR) investor relations material
Esperion Therapeutics The Citizens Life Sciences Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Financial performance and growth
Achieved 38% year-over-year total revenue growth and 34% year-over-year TRx growth, with $408 million in total revenue for the year and 11% TRx growth quarter-over-quarter.
Strong commercial access with 90% coverage in both commercial and Medicare segments, and stable gross-to-net projections.
International partnerships are driving growth, with significant contributions from Europe (notably Germany, Belgium, UK, and France) and Japan, where sales exceeded expectations.
Cash position is strong, ending the year with $168 million and improving, while continuing to deleverage and maintain financial flexibility.
Confident in sustaining growth rates, with expectations for continued momentum and no end in sight to current growth trajectory.
Strategic acquisition and integration
Acquired Corstasis for $75 million upfront and up to $180 million in milestone payments, plus low double-digit royalties, with deal expected to close in early April.
Acquisition brings a unique nasal loop diuretic, Enbumyst, approved in September 2025, targeting heart failure patients resistant to oral diuretics.
Integration plans include leveraging existing commercial infrastructure, expanding hospital and acute care coverage, and building payer access.
Global rights to the acquired product open options for expansion in Europe, Asia, and other regions.
Pre-integration activities underway, with plans to rapidly scale commercialization and awareness post-close.
Commercial strategy and market positioning
Focused on maximizing the Bempedoic acid franchise (NEXLIZET, NEXLETOL) and integrating Enbumyst into the portfolio.
Key messages to healthcare providers emphasize CLEAR Outcomes data, risk reduction, and unique benefits for statin-intolerant patients.
Digital marketing delivers strong ROI, especially in under-covered geographies, and will be further expanded.
Ongoing evaluation and expansion of field force to support both existing and new products.
Guidelines expected soon are anticipated to provide a significant tailwind for Bempedoic acid products.
Next Esperion Therapeutics earnings date
Next Esperion Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)